Meeting Preview | ‘2026 Global In-Vivo Gene Therapy Industry Development Blue Book’ to be released at the Frost & Sullivan Life Science New Investment Summit Biopharmaceutical Session

Comprehensive Overview of the In-Vivo Gene Therapy Industry Development

Systematically define the definition and treatment strategy categories of in-vivo gene therapy (including gene replacement, gene augmentation, and gene editing), compare the two delivery systems of viral and non-viral vectors, and explain their technical principles, application scenarios, and differences.

Analysis of the In-Vivo Gene Therapy Industrial Chain and Key Technical Systems

Systematically break down the complete industrial chain and key technical systems of in-vivo gene therapy from upstream production to downstream purification, focusing on core processes such as cell line development, transfection/infection system optimization, and chromatography purification. Introduce the two mainstream culture systems, HEK293 and Sf9, and analyze key bottlenecks such as low yield, high shell rate, difficulty in scaling up, high purification costs, complex quality control methods, and lack of unified standards.

Analysis of the Commercialization Prospects and Value Realization Paths of Global In-Vivo Gene Therapy

Systematically analyze the commercialization prospects of in-vivo gene therapy in key indications such as ophthalmology, blood diseases, CNS, and cardiovascular diseases, and outline the structure distribution of existing products worldwide and research pipelines in China. From a health economics perspective, explain the cost substitution logic and high pricing basis based on long-term efficacy, and analyze payment mechanisms such as installment payments, risk sharing, and commercial insurance. Combine global and Chinese market sizes, cross-border cooperation, financing activities, and BD transactions to fully reveal the industry’s business models, capital dynamics, and international development trends.

Drive Forces and Future Development Trends of Global and Chinese In-Vivo Gene Therapy Industries

Systematically analyze the driving factors and future trends of the in-vivo gene therapy industry globally and in China, including policy support, technological innovation, and quality control. This includes accelerated approval pathways, orphan drug recognition, and improved regulatory systems, along with technological advancements such as AI-driven delivery optimization, gene editing technology upgrades, and vector innovation. Further explore the long-term development direction and growth potential of the in-vivo gene therapy industry under conditions of increasing capital investment, expansion of indications from rare diseases to chronic diseases, improved regulatory frameworks, and rising demand for precision medicine.

Introduction to Global and Chinese In-Vivo Gene Therapy R&D Companies

Analyze representative key companies in the global in-vivo gene therapy field through case studies, systematically review their corporate development history and strategic positioning, and present their latest product pipelines and clinical progress. Deeply analyze the therapeutic advantages of core products in different niche indications, and combine delivery efficiency, production processes, and safety to explain the main challenges and competitive advantages they face in technology implementation and industrialization.